尤瑞克林治疗大面积脑梗死的近期及远期疗效观察  

Short and long term effect of urinary Kallidinogenase for treatment of massive cerebral infarction

作　　者：范蓉[1] 尹琳[1] 林永忠[1] 辛世萌[1] 刘丽梅[1] 郑悦[1] 

机构地区：[1]大连医科大学附属第二医院神经内科,116023

出　　处：《中华脑血管病杂志（电子版）》2011年第5期21-24,共4页Chinese Journal of Cerebrovascular Diseases(Electronic Edition)

摘　　要：目的探讨与分析尤瑞克林治疗大面积脑梗死的近期及远期临床疗效。方法 30例大面积脑梗死患者随机分为两组各15例。治疗组给予尤瑞克林及常规治疗,对照组仅给予常规治疗。于治疗前及治疗后14d,按照美国国立卫生院卒中量表(NIHSS)对两组患者进行神经功能缺损程度评定并比较;同时比较两组的病死率、临床疗效;于治疗后14d对患者进行日常生活活动能力(ADL)评分,并于发病3个月再次进行日常生活活动能力(ADL)评分,并比较。结果与治疗前相比,治疗后14d两组NIHSS评分均下降,但尤瑞克林组优于对照组(P<0.05),且临床疗效显著,总有效率、显效率显著高于对照组,病死率较对照组降低(P<0.05)。两组在治疗后3个月ADL评分较14d时均有所改善,但尤瑞克林组改善更明显(P<0.05)。结论尤瑞克林可明显改善大面积脑梗死急性期的神经功能缺损,并改善远期预后。Objective To evaluate the short and long term therapeutic effects of urinary kallidinogenase for massive cerebral infarction. Methods Thirty patients with massive cerebral infarction were randomly divided into normal treatment plus urinary kallidinogenase （UK, n = 15 ） or normal treatment （Control, n = 15 ）. National institutes of health stroke scale （NIHSS） were assessed before and 14 d after the treatment, and the clinical effects and mortality were also recorded and compared. The activities of daily living（ADL） score were assessed and compared 14 d after the treatment and 3 months after outbreak. Results After 14 d, NIHSS of both UK and control groups were decreased as compared with the pretreatment ,the decrease of NIHSS in UK group was more significant than that in control group （ P 〈 0.05 ）. The total improvement rate and total response rate of UK group significantly increased than that of control group. The mortality of UK group was lower than that of control group （P 〈 0.05 ）. After 30 d, ADL of both UK and control group were increased as compared with 14 d after the treatment. The increase of ADL in UK group was more significant than that in control group（ P 〈 0.05 ）. Conclusions Urinary kallidinogenase can obviously improve neurologic impairment in acute stage and prognosis in long-term of massive cerebral infarction.

关 键 词：尤瑞克林 脑梗死 近期疗效 远期预后 

分 类 号：R743.3[医药卫生—神经病学与精神病学]